A
Arlan Richardson
Researcher at University of Oklahoma Health Sciences Center
Publications - 288
Citations - 26618
Arlan Richardson is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Oxidative stress & Superoxide dismutase. The author has an hindex of 76, co-authored 272 publications receiving 23411 citations. Previous affiliations of Arlan Richardson include Washington University in St. Louis & University of Michigan.
Papers
More filters
Journal ArticleDOI
Geroscience: Linking Aging to Chronic Disease
Brian K. Kennedy,Shelley L. Berger,Anne Brunet,Judith Campisi,Judith Campisi,Ana Maria Cuervo,Elissa S. Epel,Claudio Franceschi,Gordon J. Lithgow,Richard I. Morimoto,Jeffrey E. Pessin,Thomas A. Rando,Thomas A. Rando,Arlan Richardson,Eric E. Schadt,Tony Wyss-Coray,Tony Wyss-Coray,Felipe Sierra +17 more
TL;DR: Mammalian aging can be delayed with genetic, dietary, and pharmacologic approaches, and it is critical to expand geroscience research directed at extending human healthspan.
Journal ArticleDOI
Trends in oxidative aging theories
Florian L. Muller,Michael S. Lustgarten,Youngmok C. Jang,Arlan Richardson,Arlan Richardson,Holly Van Remmen,Holly Van Remmen +6 more
TL;DR: It is argued that a tentative case for oxidative stress as a life-span determinant can be made in Drosophila melanogaster, and where the free radical theory is headed is discussed, specifically, telomere/cell senescence, genomic instability, and the mitochondrial hypothesis of aging.
Journal ArticleDOI
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Dudley W. Lamming,Lan Ye,Pekka Katajisto,Marcus D. Goncalves,Maki Saitoh,Deanna Stevens,James G. Davis,Adam B. Salmon,Arlan Richardson,Rexford S. Ahima,David A. Guertin,David M. Sabatini,Joseph A. Baur +12 more
TL;DR: In this article, the authors demonstrate that rapamycin disrupted a second mTOR complex, mTORC2, in vivo and that mTORc2 was required for the insulin-mediated suppression of hepatic gluconeogenesis.
Journal ArticleDOI
Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease
Patricia Spilman,Natalia Podlutskaya,Matthew J. Hart,Jayanta Debnath,Olivia Gorostiza,Dale E. Bredesen,Arlan Richardson,Randy Strong,Veronica Galvan +8 more
TL;DR: It is shown that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of Aβ42, a major toxic species in AD, in the PDAPP transgenic mouse model.
Journal ArticleDOI
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau EFFECTS ON COGNITIVE IMPAIRMENTS
Antonella Caccamo,Smita Majumder,Arlan Richardson,Arlan Richardson,Randy Strong,Randy Strong,Salvatore Oddo +6 more
TL;DR: The results presented here provide a molecular basis for the Abeta-induced cognitive deficits and, moreover, show that rapamycin, an FDA approved drug, improves learning and memory and reduces Abeta and Tau pathology.